Popular on TelAve
- Southland Symphony Orchestra Season Opener – A Musical Mosaic
- SQHWYD Launches Cognitive Finance Platform with Intelligent Trading Technology and Unified DeFi Access for Brazilian Market
- Keyanb Crypto Exchange Unveils Comprehensive Platform Architecture for Chilean Traders Seeking Lower Fees and Enhanced Security
- The Truth Behind Egypt's Stolen Legacy: Livestream
- Matecrypt Platform Delivers Comprehensive Solution for Argentine Traders with 200+ Cryptocurrencies and 2 Million Orders Per Second Processing
- Cryptocurrency Trading: AHRFD Enters German Market with Institutional-Grade Infrastructure
- CCHR: Prescription Psychotropics Fuel America's Addiction and Overdose Crisis
- Phoenix Advocacy Network Launches to Amplify Survivor Voices and Advance Disability Rights
- Gospel Sensation "Bible, Faith, Rembrandt aka BFR, They're Taking the World by Storm
- Digital Pharma Advances 2026: AI and Patient-Centric Strategies Transform Pharma Marketing
Similar on TelAve
- CCHR: Misinformation Clouds Debate on Psychiatric Drug Toxicology Transparency
- Bitcoin at $115K: AZETHIO Launches Exchange Targeting Institutional Compliance Requirements
- Tech gains propel Dow Jones past 47,000 as markets reach record highs amid trade tensions
- Three Cord True Wealth Management Unveils New Website for Better Client Communication
- Generation Own: Why Young Americans Are Skipping Corporate Careers to Buy Million-Dollar Businesses
- Phinge Announces Proposal to Combat Billions in Government Waste, Fraud, and Abuse with Proactive, Hardware-Verified Netverse App-Less Platform
- Taboo: The Lost Codes of Men — A Bold New Book Confronting the Crisis of Modern Manhood
- Phinge's Netverse to Redefine Clinical Trial Safety and Data Integrity with Netverse Patented, Hardware-Verified Platform
- 'Wild Hermit Wellness' Has Achieved Bestseller Status in Just 2 Months Since Launch Of Organic Skincare Line
- Wall Street's New Obsession? Tradewinds Aims to Revolutionize the $8B Gentlemen's Club Industry with National Peppermint Hippo™ Strategy $TRWD
Vesica Health Granted PLA Billing Code for AssureMDx
TelAve News/10877245
Enabling reimbursement and expanded patient access—Effective January 2026
IRVINE, Calif. - TelAve -- VESICA HEALTH®, INC., a precision diagnostics company improving the early detection and management of bladder cancer, today announced that the American Medical Association (AMA) has granted a Proprietary Laboratory Analysis (PLA) billing code for its AssureMDx™ test. The new code, effective January 2026, represents a critical de-risking milestone in Vesica Health's path to commercialization, establishing a recognized billing pathway that will enable reimbursement and support adoption of AssureMDx across the U.S. healthcare system. This achievement positions Vesica Health to accelerate revenue generation and deliver meaningful near-term value creation for our shareholders, while at the same time expanding access for patients.
"Securing a PLA code from the American Medical Association is a foundational milestone," said Christopher Thibodeau, Chief Executive Officer, Vesica Health. "It underscores the continued execution of our commercial strategy to expand access to AssureMDx, drive adoption across the healthcare system, and advance our mission to improve early detection and outcomes for patients, providers, and payers."
The AssureMDx PLA code (0613U) has been published in the AMA's Directory: https://www.ama-assn.org/practice-management/cpt/cpt-pla-codes
By establishing a clear reimbursement pathway, this milestone validates Vesica Health's position with payers, enables provider adoption, expands patient access, and demonstrates the company's ongoing commitment to all stakeholders.
More on TelAve News
About AssureMDx™
AssureMDx is a proprietary, noninvasive urine-based DNA test clinically validated to improve the early detection of bladder cancer. The assay integrates six genomic and epigenetic biomarkers—DNA methylation of TWIST1, OTX1, and ONECUT2, and somatic mutations in FGFR3, HRAS, and TERT—to stratify hematuria patients for expedited urologic evaluation while safely ruling out those at very low risk.
Vesica Health's genes and technology have been reported in more than 26 peer-reviewed publications involving over 8,500 patients across detection, prognostic, and predictive applications. This body of evidence includes three prospective clinical validation studies evaluating the final six-gene configuration of the AssureMDx assay for early detection. In the largest multicenter study (n=838; van Kessel et al., Journal of Urology, 2020), AssureMDx demonstrated an overall sensitivity of 96%, a negative predictive value greater than 99%, and an AUC of 0.96 for bladder cancer detection. Answering the clinical community's call for earlier, more accurate detection, AssureMDx achieved a combined sensitivity of 95.9% for Stage 0 (Ta and Tis/CIS) and Stage I disease—underpinning its unique ability to identify patients at increased risk for bladder cancer at its earliest and most treatable stages.
AssureMDx has been recognized in the AUA Clinical Guidelines as a validated urine-based genomic test for the evaluation of patients with intermediate-risk microscopic hematuria, further reinforcing its clinical utility within the standard of care.
More on TelAve News
About Vesica Health®, Inc.
Vesica Health is a privately held precision diagnostics company pioneering noninvasive solutions for the early detection and management of bladder cancer. Hematuria—blood in the urine—affects more than 17 million U.S. adults annually, yet only 12% are referred for urologic evaluation, resulting in an estimated 20,000 missed bladder cancer diagnoses each year.
Headquartered in Irvine, California, Vesica operates a CAP-accredited, CLIA-certified laboratory and holds worldwide commercialization rights for AssureMDx. The company is led by an experienced team with a proven track record in diagnostic development, clinical evidence generation, and commercial execution. In addition to its flagship assay, Vesica is advancing a pipeline that includes recurrence monitoring, prognostic, and predictive companion diagnostics.
Vesica Health is positioned to lead in the $6 billion bladder cancer diagnostics market, with a mission to improve survival and patient care through earlier detection, precision diagnostics, and expanded access to noninvasive solutions. Learn more at: www.vesicahealth.com.
For investment and partnership inquiries, or to learn more about AssureMDx, please contact Vesica Health Corporate Communications at: public.relations@vesicahealth.com
NOTE: The Vesica Health wordmarks and logos, including Vesica Health, and AssureMDx are trademarks or registered trademarks of Vesica Health, Inc. All other trademarks and service marks are the property of their respective owners.
"Securing a PLA code from the American Medical Association is a foundational milestone," said Christopher Thibodeau, Chief Executive Officer, Vesica Health. "It underscores the continued execution of our commercial strategy to expand access to AssureMDx, drive adoption across the healthcare system, and advance our mission to improve early detection and outcomes for patients, providers, and payers."
The AssureMDx PLA code (0613U) has been published in the AMA's Directory: https://www.ama-assn.org/practice-management/cpt/cpt-pla-codes
By establishing a clear reimbursement pathway, this milestone validates Vesica Health's position with payers, enables provider adoption, expands patient access, and demonstrates the company's ongoing commitment to all stakeholders.
More on TelAve News
- Three Cord True Wealth Management Unveils New Website for Better Client Communication
- Generation Own: Why Young Americans Are Skipping Corporate Careers to Buy Million-Dollar Businesses
- Dongsheng's Titanium Recycling Business Enters Aerospace Sector by 2025
- Crowdfunding Campaign Tips Off for 'NAWFSIDE' Short Film Highlighting Pressure in Youth Sports
- Icarus IFE Systems Launches the Icarus One Portable Inflight Entertainment System — The World's Most Advanced Offline AI-Driven IFE Platform
About AssureMDx™
AssureMDx is a proprietary, noninvasive urine-based DNA test clinically validated to improve the early detection of bladder cancer. The assay integrates six genomic and epigenetic biomarkers—DNA methylation of TWIST1, OTX1, and ONECUT2, and somatic mutations in FGFR3, HRAS, and TERT—to stratify hematuria patients for expedited urologic evaluation while safely ruling out those at very low risk.
Vesica Health's genes and technology have been reported in more than 26 peer-reviewed publications involving over 8,500 patients across detection, prognostic, and predictive applications. This body of evidence includes three prospective clinical validation studies evaluating the final six-gene configuration of the AssureMDx assay for early detection. In the largest multicenter study (n=838; van Kessel et al., Journal of Urology, 2020), AssureMDx demonstrated an overall sensitivity of 96%, a negative predictive value greater than 99%, and an AUC of 0.96 for bladder cancer detection. Answering the clinical community's call for earlier, more accurate detection, AssureMDx achieved a combined sensitivity of 95.9% for Stage 0 (Ta and Tis/CIS) and Stage I disease—underpinning its unique ability to identify patients at increased risk for bladder cancer at its earliest and most treatable stages.
AssureMDx has been recognized in the AUA Clinical Guidelines as a validated urine-based genomic test for the evaluation of patients with intermediate-risk microscopic hematuria, further reinforcing its clinical utility within the standard of care.
More on TelAve News
- AEI Stands Firmly with Pakistani Aircraft Engineers facing retaliation for reporting safety concerns
- Literary fiction novel- 'Skylark' wins Bronze Medal
- Kaltra unveils reversible microchannel coils – engineered for modern heat pumps
- Phinge Announces Proposal to Combat Billions in Government Waste, Fraud, and Abuse with Proactive, Hardware-Verified Netverse App-Less Platform
- Taboo: The Lost Codes of Men — A Bold New Book Confronting the Crisis of Modern Manhood
About Vesica Health®, Inc.
Vesica Health is a privately held precision diagnostics company pioneering noninvasive solutions for the early detection and management of bladder cancer. Hematuria—blood in the urine—affects more than 17 million U.S. adults annually, yet only 12% are referred for urologic evaluation, resulting in an estimated 20,000 missed bladder cancer diagnoses each year.
Headquartered in Irvine, California, Vesica operates a CAP-accredited, CLIA-certified laboratory and holds worldwide commercialization rights for AssureMDx. The company is led by an experienced team with a proven track record in diagnostic development, clinical evidence generation, and commercial execution. In addition to its flagship assay, Vesica is advancing a pipeline that includes recurrence monitoring, prognostic, and predictive companion diagnostics.
Vesica Health is positioned to lead in the $6 billion bladder cancer diagnostics market, with a mission to improve survival and patient care through earlier detection, precision diagnostics, and expanded access to noninvasive solutions. Learn more at: www.vesicahealth.com.
For investment and partnership inquiries, or to learn more about AssureMDx, please contact Vesica Health Corporate Communications at: public.relations@vesicahealth.com
NOTE: The Vesica Health wordmarks and logos, including Vesica Health, and AssureMDx are trademarks or registered trademarks of Vesica Health, Inc. All other trademarks and service marks are the property of their respective owners.
Source: Vesica Health, Inc.
Filed Under: Financial
0 Comments
Latest on TelAve News
- Tailored Events Unveils Rapid-Launch Pilot Package — Go Live in 14 Days with Weekly Conversion Scorecards
- Tobu Railway Group Will Host the Fourth Annual "Take-Akari" Bamboo Lantern Festival in East Tokyo, November 7, 2025 – January 31, 2026
- New Article by Roy J. Meidinger – Examines Hidden Hidden Healthcare Kickbacks
- Why Generic Platforms Fail in Emerging Markets: Bettorify Exposes the Gap Between Promise and Reality
- Are You Ready? Phinge Magnetically Attachable 360° Folding Smartphones-to-Tablets Gateway to Netverse App-less Rewards-based Platform & AI are Coming
- Blogging Pioneer Sherry Bennett Celebrates 29 Years Online - Sharing the Secrets Behind Her 7-Figure Blog Empire
- Koplon Dentistry Elevates Implant Expertise with Advanced CE Course
- i2 Group Acquisitions and Investments in Innovations Deliver 40% Increase in Year-on-Year Bookings
- Integra Networks Expands UK SD-WAN and Hybrid Connectivity Services for Businesses and Remote Workers
- New Book Release: The Tree That Could Not Change
- BayWa r.e. Solar Trade and WHES Announce Distribution Partnership for the European Market: Delivering Smarter Energy Storage
- Never Charge Your Smartwatch Again: Phinge's Smartwatches with Interchangeable/Chargeable Battery Bezels to be a Gateway to Netverse App-less Platform
- Fleet Mining Cloud Mining Platform — Latest Guide: Making Bitcoin Mining Safer and More Convenient
- Keebos Launches Crossbody Cases for Every iPhone 17 Model
- WOA Crypto redefines cloud Bitcoin mining, offering free access and instant profit opportunities
- Pepperdine University Malibu, California and Community Partners Recognized with 2025 ReadyCommunities Partnership National Service Award
- NBA Overachievers: OddsTrader Reveals Which Teams Will Exceed Expectations in 2025-26
- Crypto Betting Odds 2025: Bookmakers Review Analyzes Market Predictions and Year-End Price Lines
- The OpenSSL Corporation and the OpenSSL Foundation Celebrate the Success of the Inaugural OpenSSL Conference in Prague
- TKL Group's New Factory Commences Production, Pioneering A New Era In Global Heavy Duty Truck Parts
